

September 30, 2021

# Perimeter Medical Imaging AI to Present at Lytham Partners Fall 2021 Investor Conference

*Presentation at 12:30 p.m. ET on Tuesday, October 5, 2021*

TORONTO--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that it will present at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 12:30 p.m. ET.

A webcast of the presentation will be available on Perimeter Medical Imaging’s website at <https://ir.perimetermed.com> or <https://www.webcaster4.com/Webcast/Page/2650/42878>. The webcast will also be archived and available for replay following the live event.

Management will also be participating in virtual one-on-one meetings throughout the event, which runs from October 5-7, 2021. To arrange a meeting, please contact a Lytham Partners representative at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register at [www.lythampartners.com/fall2021invreg](http://www.lythampartners.com/fall2021invreg).

## **About Perimeter S-Series OCT**

Cleared by the U.S. FDA, Perimeter S-Series Optical Coherence Tomography (OCT) is a novel medical imaging system that provides clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system.

## **About Perimeter B-Series OCT with ImgAssist AI**

Perimeter is advancing the development of its proprietary, next-gen “ImgAssist” artificial intelligence technology under its ATLAS AI project, which is made possible, in part, by a US\$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.

## **About Perimeter Medical Imaging AI, Inc.**

With headquarters in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](http://Perimeter Medical Imaging AI) (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to

transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to [account for 30%](#) of all female cancer diagnoses this year.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210930005928/en/>

Shushu Feng

Perimeter Medical Imaging AI, Inc.

Main: 214-845-5154, Toll-free: 888-988-7465 (PINK)

[media@perimetermed.com](mailto:media@perimetermed.com)

Ben Shamsian or Joe Dorame, Lytham Partners, LLC

Direct: 646-829-9701

Main: 602-889-9700

[PINK@lythampartners.com](mailto:PINK@lythampartners.com)

Source: Perimeter Medical Imaging AI, Inc.